Source:
https://www.nature.com/articles/d41573-025-00001-502 January 2025
The FDA approved 50 new therapeutics in 2024, with green lights for a novel schizophrenia drug, a first NASH medicine and much more.
The FDA’s Center for Drug Evaluation and Research (CDER) approved 50 new small molecules, biologics and oligonucleotide therapeutics last year.
The class of 2024 was a little smaller than that of 2023, which had 55 approvals and was the second largest in the past 30 years.
The 10-year rolling average now stands at 46.5 novel approvals per year, a new high-water mark.
The article continues in the source link ...